Cost-effectiveness Analysis of First Line Pembrolizumab Monotherapy for High Programmed Cell Death Ligand 1 Expressed, Advanced Non-small Cell Lung Cancer in Japan

Overview

Journal Int J Clin Pharm

Publisher Springer

Specialties Pharmacology
Pharmacy

Date 2024 Nov 20

PMID 39565452

Authors

Kazuki Tomura

Hiroyuki Sakamaki

Shuichi Nawata

Hiroo Ishida

Katsumi Tanaka

Mari Kogo

Affiliations

Soon will be listed here.

Abstract

Background: Pembrolizumab monotherapy significantly extends progression-free and overall survival compared to platinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC), but also has a significant impact on medical costs.

Aim: To clarify the health economic evidence for selecting the first-line treatment for patients with stage IV advanced NSCLC with a programmed cell death ligand 1 tumor proportion score of 50% or greater in Japan, we assessed the cost-effectiveness of pembrolizumab monotherapy compared with that of platinum-based chemotherapy.

Method: Using a Markov model, the study simulated three health states for patients, based on clinical data and utility values from KEYNOTE-024. Transition probabilities were estimated exponentially. Direct medical costs were calculated according to the 2022 National Health Insurance Medical Fee Points and Drug Price Standards. The outcomes measured included life years, quality-adjusted life years, and incremental cost-effectiveness ratio, with sensitivity analysis performed to evaluate the effect of uncertainties.

Results: Pembrolizumab led to an additional 1.58 life years and 1.23 quality-adjusted life years at an additional cost of 7,009,888 Japanese yen (48,448 U.S. dollars [USD]), resulting in incremental cost-effectiveness ratio of 4,436,638 Japanese yen (30,663 USD) per life year and 5,699,096 Japanese yen (39,388 USD) per quality-adjusted life year. Pembrolizumab was deemed cost-effective under a threshold of 7.5 million Japanese yen (51,835 USD) per quality-adjusted life year.

Conclusion: Pembrolizumab monotherapy is a cost-effective option for the first-line treatment of advanced NSCLC with high programmed cell death ligand 1 expression in Japan, providing valuable health economic evidence for treatment selection.

References

Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin D, Pineros M . Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2018; 144(8):1941-1953. DOI: 10.1002/ijc.31937. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021; 39(21):2339-2349. PMC: 8280089. DOI: 10.1200/JCO.21.00174. View

Bhadhuri A, Insinga R, Guggisberg P, Panje C, Schwenkglenks M . Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland. Swiss Med Wkly. 2019; 149:w20170. DOI: 10.4414/smw.2019.20170. View

Chouaid C, Bensimon L, Clay E, Millier A, Levy-Bachelot L, Huang M . Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Lung Cancer. 2019; 127:44-52. DOI: 10.1016/j.lungcan.2018.11.008. View

Huang M, Lou Y, Pellissier J, Burke T, Liu F, Xu R . Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. Pharmacoeconomics. 2017; 35(8):831-844. PMC: 5548835. DOI: 10.1007/s40273-017-0527-z. View

Liao W, Huang J, Hutton D, Li Q . Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China. J Med Econ. 2019; 22(4):344-349. DOI: 10.1080/13696998.2019.1570221. View

Hu X, Hay J . First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung Cancer. 2018; 123:166-171. DOI: 10.1016/j.lungcan.2018.07.012. View

Nafees B, Stafford M, Gavriel S, Bhalla S, Watkins J . Health state utilities for non small cell lung cancer. Health Qual Life Outcomes. 2008; 6:84. PMC: 2579282. DOI: 10.1186/1477-7525-6-84. View

10.

Awano N, Izumo T, Inomata M, Kuse N, Tone M, Takada K . Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis. Jpn J Clin Oncol. 2021; 51(5):778-785. DOI: 10.1093/jjco/hyaa258. View

11.

Awano N, Izumo T, Inomata M, Kuse N, Tone M, Takada K . Medical costs of Japanese lung cancer patients during end-of-life care. Jpn J Clin Oncol. 2021; 51(5):769-777. DOI: 10.1093/jjco/hyaa259. View

12.

Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S . Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling. Expert Rev Pharmacoecon Outcomes Res. 2017; 17(2):153-164. DOI: 10.1080/14737167.2017.1311210. View